Abstract | BACKGROUND: METHODS: One-hundred sixteen pediatric ESA-naïve subjects (aged 1-18 years) with CKD stages 3-5D and hemoglobin (Hb) <10 g/dl from 43 centers in the US, Europe, and Mexico were randomized by age (three groups) and dialysis status (yes vs. no) to receive darbepoetin alfa once weekly (QW) or every 2 weeks (Q2W) subcutaneously (not on dialysis and peritoneal dialysis subjects) and intravenously ( hemodialysis subjects). The drug was titrated to achieve Hb levels of 10.0-12.0 g/dl over 25 weeks. Patient- and parent-reported health-related outcomes were measured by the Pediatric Quality of Life Inventory (PedsQL™) in children ≥2 years. RESULTS: In both groups, mean Hb concentrations increased to ≥11.0 g/dl over the first 3 months of treatment and remained stable within the 10.0-12.0 g/dl target range. The median time to achieve hemoglobin ≥10 g/dl was slightly longer for subjects <12 years (QW and Q2W, both 28 days) vs. those ≥12 years (23 and 22 days, respectively). Adverse event profiles were similar between groups, with QW, four (7%) and Q2W, five (9%). PedsQL™ scores showed modest increases. CONCLUSIONS:
Darbepoetin alfa can be safely administered either QW or Q2W to ESA-naïve pediatric patients with CKD-related anemia to achieve Hb targets of 10.0-12.0 g/dl.
|
Authors | Bradley A Warady, John Barcia, Nadine Benador, Augustina Jankauskiene, Kurt Olson, Ludmila Podracka, Aleksey Shavkin, Poyyapakkam Srivaths, Cynthia J Wong, Jeffrey Petersen |
Journal | Pediatric nephrology (Berlin, Germany)
(Pediatr Nephrol)
Vol. 33
Issue 1
Pg. 125-137
(Jan 2018)
ISSN: 1432-198X [Electronic] Germany |
PMID | 28815341
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Hematinics
- Hemoglobins
- Darbepoetin alfa
|
Topics |
- Adolescent
- Anemia
(drug therapy, etiology)
- Child
- Child, Preschool
- Darbepoetin alfa
(administration & dosage, adverse effects)
- Double-Blind Method
- Drug Administration Schedule
- Europe
- Female
- Hematinics
(administration & dosage, adverse effects)
- Hemoglobins
(analysis, drug effects)
- Humans
- Infant
- Male
- Mexico
- Quality of Life
- Renal Dialysis
- Renal Insufficiency, Chronic
(complications, drug therapy)
- Survival Analysis
- Treatment Outcome
|